ARHGEF37: A Potential Drug Target Or Biomarker (G389337)

Target Name: ARHGEF37

NCBI ID: G389337

ARHGEF37

Other Name(s): ARH37_HUMAN | Rho guanine nucleotide exchange factor 37 | Rho guanine nucleotide exchange factor (GEF) 37

ARHGEF37: A Potential Drug Target Or Biomarker

ARHGEF37 (ARH37_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the ARHGND family, which is characterized by the presence of a unique G-coupled sphingomyelin lipid-binding domain. This domain is known to be involved in the regulation of cellular signaling pathways, and is thought to play a role in the function of many different cellular processes.

One of the unique features of ARHGEF37 is its ability to interact with other proteins that are known to be involved in the regulation of cellular signaling pathways. This interaction has led some researchers to consider that ARHGEF37 may be a drug target or biomarker for a variety of diseases.

One of the potential benefits of targeting ARHGEF37 is its potential to modulate the activity of signaling pathways that are involved in the development and progression of many different diseases. For example, some studies have suggested that ARHGEF37 may be involved in the regulation of angiogenesis, the process by which new blood vessels are formed. This is thought to be involved in the development of many diseases, including cancer, cardiovascular disease, and diabetes.

In addition to its potential role in the regulation of angiogenesis, ARHGEF37 has also been shown to be involved in the regulation of cellular signaling pathways that are involved in the development and progression of many other diseases. For example, some studies have suggested that ARHGEF37 may be involved in the regulation of the Wnt signaling pathway, which is involved in the development and maintenance of the nervous system. This is thought to be involved in the development of many diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Another potential benefit of targeting ARHGEF37 is its potential to serve as a biomarker for disease. This is because some studies have suggested that ARHGEF37 may be expressed in the urine and other body fluids, which could make it a useful biomarker for a variety of diseases. For example, some studies have suggested that ARHGEF37 may be expressed in the urine of patients with cancer, and that this may be a useful indicator of the presence of this disease.

In conclusion, ARHGEF37 is a protein that is expressed in various tissues of the human body, and is known to be involved in the regulation of cellular signaling pathways. Its unique ability to interact with other proteins that are involved in the regulation of cellular signaling pathways has led some researchers to consider that ARHGEF37 may be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of ARHGEF37 in the regulation of cellular signaling pathways and its potential as a drug target or biomarker.

Protein Name: Rho Guanine Nucleotide Exchange Factor 37

Functions: May act as a guanine nucleotide exchange factor (GEF)

The "ARHGEF37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets